EU/3/10/808

About

On 26 November 2010, orphan designation (EU/3/10/808) was granted by the European Commission to ADIENNE S.r.l., Italy, for murine monoclonal antibody against CD26 for the treatment of graft-versus-host disease.

In January 2014, ADIENNE S.r.l. changed name to ADIENNE S.r.l.S.U.

For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.

Key facts

Active substance
Murine monoclonal antibody against CD26
Disease / condition
Treatment of graft-versus-host disease
Date of decision
26/11/2010
Outcome
Positive
Orphan decision number
EU/3/10/808

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

ADIENNE S.r.l.S.U.
Via Galileo Galilei, 19
20867 Caponago (MB)
Italy
Tel. +39 02 4070 0445
Fax +39 02 9574 5179
E-mail: adienne@adienne.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating